Thus, clinical application of new therapeutic agents that target the fractalkine/CX3CR1 axis could be applied in the high risk DLBCL patients with high percentage of PB-CD11b+CX3CR1+ monocytes. The gene discussed is CX3CR1; the disease is diffuse large B-cell lymphoma.